An interventional study of Digital Patient-Reported Assessment Pathway in Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia, sponsored by Fundación para la Investigación Biosanitaria del Principado de Asturias. Not yet recruiting at 1 site in Spain. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.
Sponsored by Fundación para la Investigación Biosanitaria del Principado de Asturias · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 200 studies in Leukemia, Myeloid, Acute with a site in Spain — 35 open to participants now, 61 under way, 22 of them phase 3. Leukemia, Myeloid, Acute · Spain.
Among the 200 studies in Leukemia, Myeloid, Acute with a site in Spain, this one is the 170th largest by planned enrollment of the 189 interventional ones that give a count, is one of 7 that started in 2026, is one of 3 with no phase, reaches primary completion later than 35 of the 60 other live ones, and was the 200th registered.
3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.
Browse Leukemia, Myeloid, Acute studies →35 of the 200 studies in Leukemia, Myeloid, Acute with a site in Spain are open now. Recruiting first, the newest first:
PETHEMA Foundation · Sites in Spain
Ages 18+
AbbVie · Sites in Spain, United States, Austria and 4 more countries
Ages 18+
PETHEMA Foundation · Sites in Spain, Portugal
Ages 18+
Stichting Hemato-Oncologie voor Volwassenen Nederland · Sites in Spain, United States, Australia and 10 more countries
Ages 18+
Genmab · Sites in Spain, Denmark, Italy
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
200 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 88 · Phase 2 80 · Phase 3 61 · Phase 4 5
First in 1998; this study’s year is marked. 7 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 40 across 3,010 interventional studies indexed under Leukemia, Myeloid, Acute.
Median enrollment 120 across the 189 interventional studies, 600 across the 11 observational. Of the 134 that completed or were terminated, 72 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
148 of 200 have an industry lead sponsor. The 10 most frequent:
Fundación para la Investigación Biosanitaria del Principado de Asturias is the lead sponsor of 13 studies on the registry; 6 are open to participants now.
Fundación para la Investigación Biosanitaria del Principado de Asturias has 1 study filed under Leukemia, Myeloid, Acute — fewer than ten, so there is no comparison to draw.
20 of the studies in Leukemia, Myeloid, Acute with a site in Spain that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05183035Phase 3PedAL BCU, LLCVenetoclax in Children With Relapsed Acute Myeloid Leukemia (AML) | 2027-02 |
| NCT03839771Phase 3Stichting Hemato-Oncologie voor Volwassenen NederlandA Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy | 2027-04-17 |
| NCT05429632Phase 3Priothera SASMocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT | 2027-05 |
| NCT03844048Phase 3AbbVieAn Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial | 2027-08 |
| NCT04256317Phase 3Taiho Oncology, Inc.A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study) | 2027-11-01 |
Add all 20 to your calendar (.ics) → With an account.
Among the 200 studies in Leukemia, Myeloid, Acute with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This pilot study will evaluate the feasibility of implementing a structured digital patient-reported assessment pathway in adults aged 65 years or older with acute leukemia at Hospital Universitario Central de Asturias, Oviedo, Spain. Participants will complete the EORTC QLQ-C30 and FACT-Leu remotely after the baseline visit and repeat the digital assessment 8-12 weeks after individual activation of the MiAsturSalud/SESPA digital pathway. The primary outcome will be the proportion of participants answering at least 80% of the items in the baseline digital questionnaire battery within 7 days after the baseline visit. Secondary outcomes will be caregiver assistance requirement, non-completion of the planned digital follow-up assessment, and elapsed baseline questionnaire completion time. During this feasibility study, participants will not concurrently receive the broader project's home-monitoring and clinical-alert intervention. The questionnaire pathway will not generate automated clinical alerts. Usual clinical care will continue. The study is not designed to establish clinical efficacy.
This study evaluates the implementation of a digital questionnaire pathway within the institutional MiAsturSalud/SESPA platform at Hospital Universitario Central de Asturias, Oviedo, Spain. It constitutes a defined feasibility component of the broader CEImPA 2025.519 project.
The baseline digital assessment will be scheduled 48-72 hours after the baseline visit. Responses saved within 7 days after that visit will contribute to the primary outcome. The follow-up digital assessment will take place during the window of 8-12 weeks after individual activation of the digital pathway.
The questionnaire battery comprises the 30-item EORTC QLQ-C30 and the 44-item FACT-Leu, giving a total of 74 items. The platform will permit individual items to be skipped, progressively save partial responses, and allow participants to resume an incomplete assessment within the corresponding assessment window. These functions and the timestamp recording required for outcome measurement will be implemented and verified before recruitment begins.
The primary outcome will be the proportion of all enrolled participants who answer at least 80% of the baseline battery items within 7 days after the baseline visit. Meeting this criterion requires at least 60 answered items out of 74. Outcome ascertainment will use responses saved by the end of the assessment window, irrespective of formal battery submission. All enrolled participants will be included in the denominator; those with fewer than 60 answered items, including those with no recorded responses, will not meet the criterion.
The same threshold of at least 60 answered items out of 74 will define completion of the follow-up assessment within the 8-12-week window. Follow-up completion status will be determined at the end of this window, irrespective of formal battery submission. Reasons for non-completion will be recorded where ascertainable and reported separately, distinguishing technical or participation-related barriers from clinical events preventing assessment.
Elapsed baseline completion time will be measured in minutes from the first saved item response to the first time at which at least 60 distinct items have saved responses. This measure will be calculated among participants who reach the threshold within the 7-day baseline window. It will include pauses and intervals between sessions and will not be interpreted as active questionnaire completion time. Participants who do not reach the threshold will not be assigned a completion time; their number will be reported separately.
The item-completion criterion is an operational measure of implementation feasibility and is separate from the instrument-specific rules for calculating questionnaire scores. The 80% threshold is a pragmatic criterion and is not an externally validated benchmark or a stand-alone progression rule. The participant-level feasibility estimate and its 95% confidence interval will be interpreted alongside item-completion patterns, caregiver assistance, follow-up non-completion and its reasons, and elapsed time to the baseline completion threshold to identify modifications needed before a larger evaluation.
Throughout this component's baseline and follow-up period, participants will not concurrently receive the broader project's home-monitoring and clinical-alert intervention. The study questionnaire pathway will not generate automated clinical alerts or mandate treatment changes. Home monitoring and clinical-alert functions are planned for a subsequent phase and are outside the scope of this registered feasibility study. Usual clinical care will continue.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: Digital Patient-Reported Assessment Pathway
Following individual activation of the MiAsturSalud/SESPA digital pathway, participants will complete the EORTC QLQ-C30 and FACT-Leu remotely. The baseline assessment will be scheduled 48-72 hours after the baseline visit, with a primary outcome assessment window extending to 7 days after that visit. A second digital assessment will be scheduled 8-12 weeks after individual pathway activation. The platform will permit skipped items, save partial responses, and allow participants to resume the baseline assessment within the 7-day window. Questionnaire item responses and timing data will be recorded, and practical caregiver assistance will be documented. The questionnaire pathway will not generate automated clinical alerts or mandate treatment changes. Participants will not concurrently receive the broader project's home-monitoring and clinical-alert intervention during this feasibility study. Usual clinical care will continue.
Feasibility of Digital Implementation
Percentage of all enrolled participants who answer at least 80% of the 74 items in the baseline digital questionnaire battery comprising the EORTC QLQ-C30 and FACT-Leu within 7 days after the baseline visit. Meeting this criterion requires at least 60 answered items. The numerator will include participants meeting this criterion, and the denominator will include all enrolled participants. Responses saved within the assessment window will count irrespective of formal battery submission. Participants with fewer than 60 answered items, including those with no recorded responses, will not meet the criterion. Individual items may be skipped; the 74-item denominator does not imply mandatory responses. The percentage will be reported with a 95% confidence interval.
Time frame: Within 7 days after the baseline visit.
Caregiver Assistance Requirement
Proportion of participants requiring practical caregiver assistance to access or navigate the platform, read questionnaire content or enter responses selected by the participant. Independent proxy completion will not be permitted.
Time frame: Within 7 days after the baseline visit.
Non-completion of Planned Digital Follow-up Assessment
Proportion of all enrolled participants who do not answer at least 60 of the 74 items in the EORTC QLQ-C30 and FACT-Leu follow-up digital questionnaire battery during the assessment window of 8-12 weeks after individual digital pathway activation. Completion will be determined from responses saved within this window, irrespective of formal battery submission. Participants with fewer than 60 answered items, including those with no recorded follow-up responses, will be classified as not completing the follow-up assessment. Reasons will be recorded where ascertainable, including voluntary withdrawal, technical difficulties, clinical deterioration, disease progression, hospitalization, death, and loss to follow-up, and reported separately.
Time frame: 8-12 weeks after individual digital pathway activation.
Elapsed Time to Reach the Baseline Questionnaire Completion Threshold
Elapsed time, in minutes, between the first saved item response in the baseline digital questionnaire battery and the first time at which at least 60 distinct items out of 74 have saved responses. This measure will be calculated among participants who reach this threshold within 7 days after the baseline visit, using platform timestamps. Elapsed time will include pauses and intervals between sessions and will not be interpreted as active questionnaire completion time. Participants who do not reach the threshold will not be assigned a completion time; their number will be reported separately.
Time frame: Within 7 days after the baseline visit.
Plan to share: Yes — De-identified individual participant data underlying results reported in publications arising from this study, together with the corresponding data dictionary and statistical analysis code, will be available from the principal investigators upon reasonable request. Access will be subject to a methodologically sound proposal, institutional governance review, an appropriate data-use agreement and applicable ethics and data-protection requirements. Owing to the small sample size and risk of re-identification, participant-level data will not be deposited in an openly accessible public repository.
Supporting information: Study protocol, Analytic code
Time frame: Beginning 6 months after publication of the principal study results and ending 5 years thereafter.
Access criteria: Requests must include a methodologically sound research proposal and will be subject to approval by the principal investigators and relevant institutional governance bodies. Access will require an appropriate data-use agreement and compliance with applicable ethics and data-protection requirements
Start is estimated for Dec 2026; primary completion for Dec 2027, 12 months later.
Of 132 non-industry interventional studies with no phase under Leukemia, Myeloid, Acute, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 128. This study's planned 12 months is below that.
Counting every sponsor, half of 139 studies reached it within 47 months; a quarter within 25 and three quarters within 123.
Completion moved once since we started tracking on Sep 25, 2026: Jun 2028 → Mar 2028, on Oct 7, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fundación para la Investigación Biosanitaria del Principado de Asturias